Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Larosa

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Cleveland Clinic Journal of Medicine|January 6, 2006
Use of corticosteroids in the sepsis syndrome: what do we know now?Steven P LaRosa
Cleveland Clinic Journal of Medicine|January 29, 2002
Sepsis: menu of new approaches replaces one therapy for allSteven P Larosa
Critical Care (London, England)|May 26, 2010
Activated protein C for H1N1 influenza? More work to do!Steven P LaRosa
Expert Review of Anti-Infective Therapy|May 26, 2011
Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsisMark Tidswell, Steven P LaRosa
Clinics in Chest Medicine|October 29, 2008
Sepsis strategies in developmentSteven P LaRosa, Steven M Opal
Current Infectious Disease Reports|August 2, 2012
Immune aspects of sepsis and hope for new therapeuticsSteven P Larosa, Steven M Opal
The Lancet. Infectious Diseases|July 20, 2012
Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregressionAndre C Kalil, Steven P LaRosa
Critical Care Clinics|March 29, 2011
Biomarkers: the futureSteven P LaRosa, Steven M Opal
Critical Care (London, England)|November 6, 2009
Year in review 2008: Critical Care--sepsisSteven M Opal, Steven P LaRosa
Cutis|June 9, 2004
Antibiotics: what's new?Steven P LaRosa, Kenneth J Tomecki
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Cleveland Clinic Journal of Medicine|January 6, 2006
Use of corticosteroids in the sepsis syndrome: what do we know now?Steven P LaRosa
Cleveland Clinic Journal of Medicine|January 29, 2002
Sepsis: menu of new approaches replaces one therapy for allSteven P Larosa
Critical Care (London, England)|May 26, 2010
Activated protein C for H1N1 influenza? More work to do!Steven P LaRosa
Expert Review of Anti-Infective Therapy|May 26, 2011
Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsisMark Tidswell, Steven P LaRosa
Clinics in Chest Medicine|October 29, 2008
Sepsis strategies in developmentSteven P LaRosa, Steven M Opal
Current Infectious Disease Reports|August 2, 2012
Immune aspects of sepsis and hope for new therapeuticsSteven P Larosa, Steven M Opal
The Lancet. Infectious Diseases|July 20, 2012
Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregressionAndre C Kalil, Steven P LaRosa
Critical Care Clinics|March 29, 2011
Biomarkers: the futureSteven P LaRosa, Steven M Opal
Critical Care (London, England)|November 6, 2009
Year in review 2008: Critical Care--sepsisSteven M Opal, Steven P LaRosa
Cutis|June 9, 2004
Antibiotics: what's new?Steven P LaRosa, Kenneth J Tomecki
Pageof 4